As the main clinical drug with high-level evidence used to treat AMD and DR, anti-VEGF agents had a stronger disturbance to the disease network than other types of adjuvant therapy (including growth factors, corticosteroids, anticoagulants, angiotensin II receptor blockers, and so on), which indicates that this algorithm has a good prediction performance for drug positioning. This evidence concerns the gene VEGFA and age-related macular degeneration.